Big Pharma R&D Chiefs On IRA’s Unintended Casualty, Product Life Cycle Compression
Executive Summary
R&D heads of Takeda, Amgen, Lilly and Novartis discuss some of the tectonic forces shaping the biopharma sector and the unintended consequences of the IRA on small molecule innovation. Advances in the neurodegenerative diseases segment amid impressive data from donanemab was another key talking point.
You may also be interested in...
What’s In Store For CROs, CDMOs – “Stay In Your Swim Lane”, Consolidation, Divestitures
Brian Scanlan, operating partner (life sciences), Edgewater Capital Partners, in an interview with Scrip, outlines where things may be headed in the CRO/CDMO segment amid big pharma streamlining efforts, “belt tightening” by emerging biopharma, down rounds and heightened geopolitical tension.
Former VA Secretary, Biogen Exec On IRA And Politics, Price Clamps In Europe
A former secretary of the US Department of Veterans Affairs and a senior Biogen executive deliberated at a recent summit the unintended consequences of the US Inflation Reduction Act and politics around the legislation. They likened the first prescription drugs subject to price controls under the IRA to a “TV commercial list.”
India Clinical Trials Scenario: Leaders From Novartis, IQVIA, PwC Signal Winds Of Change
Leaders from Novartis, IQVIA and PwC discuss the ground situation for trials in India as regulatory reforms, improved infrastructure and clinical expertise provide opportunities. Potential in areas like orphan diseases and tips for peer Amgen on getting trials going in India were among other highlights.